
Galvanize Therapeutics Closes $130M Series D to Expand Pulsed Electric Field Cancer Surgery
A New Category of Cancer Surgery Is Gaining Ground
Surgical ablation has long been a mainstay of oncology, but its dominant modalities, thermal radiofrequency and microwave techniques, face inherent limitations: heat spreads unpredictably, damages adjacent tissue, and cannot reliably reach tumors near critical structures. For years, the field has searched for a more precise mechanism. Pulsed electric field therapy, which destroys cells by disrupting their membranes with controlled electrical pulses rather than heat, is now one of the most closely watched answers.
Galvanize Therapeutics, based in Redwood City, California, is among the leading developers of this approach. On November 16, 2026, the company announced it had closed an oversubscribed $130 million Series D round to scale its platform.
What Galvanize Therapeutics Has Built
Galvanize Therapeutics develops surgical ablation devices using pulsed electric field energy, a modality it is advancing across multiple soft-tissue cancer indications. PEF therapy works by applying precisely calibrated electrical pulses that create irreversible disruption of cell membranes, triggering cell death without relying on thermal diffusion. The result is a mechanism that can destroy tumor tissue with sharper boundaries than thermal approaches allow, with the potential to treat lesions near vessels, nerves, or other sensitive anatomy where thermal ablation carries higher risk.
The company's lead program targets solid soft-tissue tumors and has advanced through clinical evaluation with encouraging results that have attracted the attention of leading oncology centers. Its platform is designed for use by interventional oncologists and surgeons working across ablation-amenable cancer indications. The company holds a portfolio of intellectual property covering its PEF device architecture and treatment protocols.
The Series D Round
The $130 million oversubscribed Series D was led by existing investors and drew additional institutional capital into the syndicate. The round was oversubscribed, a signal of investor conviction in the company's clinical and commercial trajectory. Galvanize has now raised substantial cumulative capital across multiple rounds to advance its PEF platform from early development toward broader clinical deployment.
The capital will be deployed to continue clinical development across the company's pipeline, expand its manufacturing capabilities, and build toward regulatory milestones in the United States and potentially additional jurisdictions. The company has previously engaged with the FDA as it advances its devices through the regulatory pathway required for surgical ablation systems.
Why Pulsed Electric Field Therapy Matters
Cancer surgery and ablation represent a large and growing global market. Approximately 10 million people die of cancer annually, and surgical intervention, including ablation, is a component of standard care for a broad range of solid tumors. The limitations of thermal ablation have been a recognized clinical problem for decades: thermal energy is difficult to confine, particularly in regions with high blood flow that acts as a heat sink, and thermal damage to adjacent critical structures is a persistent concern.
PEF therapy addresses these constraints through a fundamentally different physical mechanism. By operating non-thermally, PEF devices can potentially treat tumors in locations where thermal ablation is contraindicated or carries excessive risk. If the clinical evidence continues to support the approach across a range of indications, PEF could expand the population of patients eligible for ablative treatment.
Galvanize is not alone in developing PEF technology, and clinical validation at scale remains the central challenge for the field. But the company's oversubscribed round, combined with its clinical progress, suggests it has built meaningful credibility with both investors and clinical partners.
What Comes Next
The company plans to use the Series D proceeds to advance its clinical program, expand manufacturing, and pursue regulatory approvals that would allow it to commercialize its devices more broadly. Each of those steps requires sustained execution over a multi-year horizon.
The oversubscription of the round is a data point worth noting in a capital environment that has been selective in medtech. It suggests that the investors participating in this syndicate, who have visibility into the clinical data, are sufficiently convinced of the platform's trajectory to commit additional capital at this stage.
Galvanize Therapeutics is operating in a category, non-thermal surgical ablation, that did not exist as a commercial reality five years ago. The Series D positions it to push further toward the clinical and commercial milestones that will determine whether PEF therapy becomes a standard of care in oncology.
Galvanize Therapeutics is headquartered in Redwood City, California. Source: https://galvanizetx.com
